A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Public ClinicalTrials.gov record NCT01544114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Study identification
- NCT ID
- NCT01544114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- VIMOVO 250/20 Drug
- VIMOVO 375/20 Drug
- VIMOVO 500/20 Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 16 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Jan 31, 2015
- Completion
- Jan 31, 2015
- Last update posted
- Dec 16, 2024
2012 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Little Rock | Arkansas | 72202 | — |
| Research Site | San Francisco | California | 94143 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Research Site | West Palm Beach | Florida | 33407 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Omaha | Nebraska | 68114 | — |
| Research Site | Brooklyn | New York | 11203 | — |
| Research Site | New Hyde Park | New York | 11040 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Toledo | Ohio | 43623 | — |
| Research Site | Philadelphia | Pennsylvania | 19134 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01544114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01544114 live on ClinicalTrials.gov.